In 2014, the ASA’s Biopharmaceutical Section started a safety working group (ASA BIOP-SWG) that included members from both regulatory agencies and industry. The working group initially focused on design and analysis of cardiovascular safety outcome trials for type II diabetes drugs. Later, it expanded into a systematic review of multisource safety data and corresponding analysis strategies.
Amstat News
The Membership Magazine of the American Statistical Association